EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Pharmacokinetics and Pharmacodynamics of Dapagliflozin in Obese and Nonobese Healthy Adults Following Multiple Administration

Hae Won Lee iD, Hyungjin Kim iD, Ji Seo Park, Jae Hwa Lee iD, Jin Ju Park, Mi-Ri Gwon, Joo-Youn Cho iD, Sook Jin Seong, Young-Ran Yoon iD

Drug Design, Development and Therapy · 2026-05 · Volume 20 · 1-13

DOI: 10.2147/dddt.s574016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2026-05. Verfasst von Hae Won Lee und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Kyungpook National University and Department of Clinical Pharmacology and Therapeutics, Kyungpook National University Hospital, D…. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Obesity, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, lowers blood glucose levels by preventing renal glucose reabsorption, resulting in urinary glucose excretion. Because dapagliflozin-induced glycosuria produces a modest reduction in body weight, it may benefit patients with type 2 diabetes who are overweight or obese. Pathophysiologic alterations associated with obesity may lead to clinically significant differences in drug pharmacokinetic (PK) and pharmacodynamic (PD) properties.

Purpose

This study aimed to evaluate the PK and PD characteristics of dapagliflozin in obese and nonobese healthy adults and assess the effect of obesity on these profiles by comparing outcomes between the two groups following multiple oral doses.

Methods

In this open-label, multiple-dose study, dapagliflozin 10 mg tablets were administered once daily for 5 days to healthy adults. Serial blood samples for PK analysis were collected before and up to 48 h after the last dose on day 5. PK parameters were determined using noncompartmental analysis.Sensitivity analyses were conducted, including correlation analysis of PK parameters with weight or BMI using Pearson's correlation coefficients (r), as well as analysis of covariance (ANCOVA) with body weight as a covariate, supplemented by bootstrap analysis, to evaluate the effect of obesity on the primary PK and PD parameters.

Results

Thirteen nonobese and nine obese participants completed the study. The geometric mean ratio (obese/nonobese) (90% CIs) of the area under the plasma concentration-time curve during a dosing interval at steady state (AUCtau,ss) and maximum plasma concentration at steady state (Cmax,ss) were 0.6855 (0.5503-0.8538) and 0.7673 (0.6145-0.9581), respectively. There was no moderate correlation (r > 0.6) between any of the PK parameters analyzed and weight or BMI. The ANCOVA least squares mean differences between the nonobese and obese groups were 163.6 h*ng/mL, 38.4 ng/mL, 2.4 mg/dL, for AUCtau,ss, Cmax,ss, and serum glucose levels from baseline to maximum level on day 5 (ΔGmax), respectively (p value > 0.05, ANCOVA), which were consistent with the median values of bootstrap estimates.

Conclusion

The AUCtau,ss and Cmax,ss values for the obese group were lower than those of the nonobese group (31% and 23%, respectively). The sensitivity analyses revealed no moderate correlation between the primary PK and PD parameters and weight or BMI, nor any statistically significant differences in systemic exposure and ΔGmax between the nonobese and obese groups; however, this finding should be interpreted with caution due to the exploratory nature of the study and its limited sample size. Dapagliflozin was safe and well-tolerated following multiple oral doses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsGlucosidesObesitySodium-Glucose Transporter 2 InhibitorsHypoglycemic AgentsHumansAdultMaleFemaleMiddle AgedAdministration, OralYoung AdultDose-Response Relationship, DrugBlood GlucoseTabletsHealthy Volunteers

Stichwörter der Autor:innen

dapagliflozinobesitypharmacodynamicspharmacokineticstype 2 diabetes

Substanzen

dapagliflozinBenzhydryl CompoundsGlucosidesSodium-Glucose Transporter 2 InhibitorsBlood GlucoseTabletsHypoglycemic Agents

Autor:innen und Institutionen

  • School of Medicine, Kyungpook National University and Department of Clinical Pharmacology and Therapeutics, Kyungpook National University Hospital, Daegu, 41944, Republic of Korea.
  • Department of Molecular Medicine, School of Medicine, Kyungpook National University, Daegu, 41944, Republic of Korea.
  • Clinical Omics Institute, School of Medicine, Kyungpook National University, Daegu, 41405, Republic of Korea.
  • Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.

ORCID-Profile: Hae Won Lee, Hyungjin Kim, Jae Hwa Lee, Joo-Youn Cho, Young-Ran Yoon

Zitieren

APA

Lee, H. W., Kim, H., Park, J. S., Lee, J. H., Park, J. J., Gwon, M. R., Cho, J. Y., Seong, S. J., & Yoon, Y. R. (2026). Pharmacokinetics and Pharmacodynamics of Dapagliflozin in Obese and Nonobese Healthy Adults Following Multiple Administration. Drug Design, Development and Therapy, Volume 20, 1-13. https://doi.org/10.2147/dddt.s574016

Vancouver

Lee HW, Kim H, Park JS, Lee JH, Park JJ, Gwon MR, et al. Pharmacokinetics and Pharmacodynamics of Dapagliflozin in Obese and Nonobese Healthy Adults Following Multiple Administration. Drug Design, Development and Therapy. 2026;Volume 20:1-13. doi:10.2147/dddt.s574016

BibTeX
@article{Lee2026,
  author = {Lee, Hae Won and Kim, Hyungjin and Park, Ji Seo and Lee, Jae Hwa and Park, Jin Ju and Gwon, Mi-Ri and Cho, Joo-Youn and Seong, Sook Jin and Yoon, Young-Ran},
  title = {Pharmacokinetics and Pharmacodynamics of Dapagliflozin in Obese and Nonobese Healthy Adults Following Multiple Administration},
  journal = {Drug Design, Development and Therapy},
  year = {2026},
  volume = {Volume 20},
  pages = {1--13},
  doi = {10.2147/dddt.s574016}
}
Kostenlos starten →